Michael Kim, MD
Family Medicine · Fairfax, VANPI 1144291097
Payments from drug & device makers
Across 402 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$897
- AstraZeneca$894
- Novo Nordisk$775
- Boehringer Ingelheim$688
- Pfizer$556
- Lilly USA, LLC$501
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,37298%
- Education$1872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 32 | $897 |
| AstraZeneca(2 entities) | 45 | $894 |
| Novo Nordisk | 48 | $775 |
| Boehringer Ingelheim | 32 | $688 |
| Pfizer | 32 | $556 |
| Lilly USA, LLC | 30 | $501 |
| Amgen(2 entities) | 27 | $487 |
| GSK | 22 | $398 |
| Sumitomo Pharma America, Inc. | 23 | $348 |
| Astellas Pharma US Inc | 15 | $329 |
| Johnson & Johnson | 13 | $225 |
| Merck | 15 | $202 |
| Amarin Pharma, Inc. | 9 | $172 |
| Regeneron Healthcare Solutions, Inc. | 3 | $106 |
| Esperion Therapeutics, Inc. | 6 | $104 |
| Exact Sciences | 5 | $98 |
| Abbott | 4 | $83 |
| Sunovion Pharmaceuticals Inc. | 6 | $78 |
| Vanda Pharmaceuticals Inc. | 3 | $74 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Novartis | 3 | $54 |
| IBSA Pharma Inc. | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| AbbVie | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Dynavax Technologies Corporation | 2 | $38 |
| Dexcom, Inc. | 1 | $32 |
| OPKO Pharmaceuticals, LLC | 2 | $26 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Bayer | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Ascend Therapeutics US, LLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| VBI Vaccine (delaware) Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Metacel Pharmaceuticals LLC | 1 | $10 |
How this compares
$7,559 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 246 | $314,721 |
| JanuviaSitagliptin Phosphate | 217 | $297,867 |
| EliquisApixaban | 145 | $150,630 |
| TradjentaLinagliptin | 104 | $135,451 |
| OzempicSemaglutide | 110 | $121,320 |
| MyrbetriqMirabegron | 154 | $112,193 |
| VascepaIcosapent Ethyl | 158 | $111,375 |
| XifaxanRifaximin | 23 | $81,620 |
| Lidocaine | 234 | $80,743 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $80,481 |
| FarxigaDapagliflozin Propanediol | 53 | $71,864 |
| LinzessLinaclotide | 66 | $62,247 |
| XareltoRivaroxaban | 34 | $50,516 |
| RestasisCyclosporine | 30 | $37,419 |
| Diclofenac Sodium | 83 | $33,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $688 | $464,424363 claims |
| MerckJanuvia, Janumet, Janumet Xr | $202 | $340,383247 claims |
| PfizerEliquis | $556 | $150,630145 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy | $398 | $127,407218 claims |
| Novo NordiskOzempic | $775 | $121,320110 claims |
| Astellas Pharma US IncMyrbetriq | $329 | $112,193154 claims |
| AbbVieLinzess, Restasis | $43 | $99,66796 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $39 | $81,62023 claims |
| AstraZenecaFarxiga | $894 | $71,86453 claims |
| Johnson & JohnsonXarelto | $225 | $50,51634 claims |
| Lilly USA, LLCMounjaro | $501 | $20,87721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Fairfax
- Sabeen PervaizFairfax$165K
- Garry HoFairfax$61K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.